SCHEMBL5226610

SCHEMBL5226610

COc1ccc(NC(=O)c2cc(NS(=O)(=O)c3ccccc3)ccc2NC(=O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 6/20 0.60
F10 P00742 3/20 0.59
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
PPARG P37231 3/20 0.56
PPARA Q07869 2/20 0.56
TDP1 Q9NUW8 1/20 0.55
AVPR2 P30518 2/20 0.54
GPR27 Q9NS67 2/20 0.54
CCR8 P51685 1/20 0.54
TRPV1 Q8NER1 1/20 0.54
NPC1 O15118 1/20 0.54
PPARD Q03181 1/20 0.53
GPBAR1 Q8TDU6 1/20 0.53
EGFR P00533 1/20 0.53
FGFR1 P11362 1/20 0.53
KDR P35968 1/20 0.53
TP53 P04637 1/20 0.53
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5222813 0.93 NR1H4 (0.60) NR1H4MEN1KMT2APPARGPPARA
SCHEMBL5225715 0.87 F10 (0.76) NR1H4F10MEN1KMT2APPARG
SCHEMBL5225151 0.85 F10 (0.61) NR1H4F10MEN1KMT2APPARG
SCHEMBL5225091 0.85 F10 (0.61) NR1H4F10MEN1KMT2APPARG
SCHEMBL5228531 0.82 MEN1 (0.65) NR1H4F10MEN1KMT2ATP53
SCHEMBL5223218 0.81 NR1H4 (0.73) NR1H4F10MEN1KMT2APPARG
SCHEMBL5222102 0.81 NR1H4 (0.64) NR1H4F10PPARGPPARANPC1
SCHEMBL5225486 0.80 NR1H4 (0.63) NR1H4F10MEN1KMT2APPARG
SCHEMBL5223117 0.79 F10 (0.64) NR1H4F10MEN1KMT2APPARG
SCHEMBL27179735 0.79 MEN1 (0.71) MEN1KMT2ATDP1AVPR2GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 NR1H4 2304/4885F10 12/4885MEN1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.